Drug Approval | May 10, 2024
Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Subscribe To Our Newsletter & Stay Updated
